AbSci Corporation (ABSI)

The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in ParallelJuly 6, 2026 8:45 AM
PR Newswire (US) A wave of government funding, hardware progress, and looming encryption deadlines has turned quantum from a lab curiosity into one of the most closely watched corners of the market in 2026, spanning computing hardware and the cybersecurity built to survive it.VANCOUVER, BC, July 6, 2026 /PRNewswire/ -- USA News Group News Commentary, For years, quantum computing lived mostly in research papers and conference keynotes. In 2026 it has become something harder to ignore: a sector with federal capital behind it, a string of technical milestones on the board, and a parallel race to rebuild the world's encryption before quantum machines can break it. The result is one of the most polarizing themes in the market, real scientific progress on one side, valuations that assume a commercial payoff still years away on the other. Below is a look at where the sector stands and a handful of the public companies operating across its very different lanes, from computing hardware to post-quantum security, including QSE - Quantum Secure Encryption Corp. (CSE: QSE) (OTCQB: QSEGF) (FSE: VN8). Key TakeawaysWashington has moved from rhetoric to capital, with the U.S. Department of Commerce announcing roughly $2 billion in quantum funding under the CHIPS and Science Act in May 2026, followed by a pair of executive orders on June 22, 2026 setting hard agency timelines for quantum hardware and cryptographic defense.The pure-play computing names, including IonQ, Rigetti, and D-Wave, pursue fundamentally different architectures, while big-cap programs at IBM and Alphabet carry the frontier with far deeper balance sheets.A separate but related lane, post-quantum security, is racing against fixed regulatory deadlines as organizations prepare to migrate encryption before quantum machines can break it.Names operating across these lanes include QSE - Quantum Secure Encryption Corp. (CSE: QSE), IonQ (NYSE: IONQ), Rigetti Computing (Nasdaq: RGTI), D-Wave Quantum (NYSE: QBTS), and IBM (NYSE: IBM), each distinct, each at a different scale, and none a proxy for any other.Washington Puts Money Behind the ThemeThe clearest signal that quantum has moved from speculation toward strategic priority came from the federal government. In May 2026, the U.S. Department of Commerce announced approximately $2 billion in funding for the quantum industry under the CHIPS and Science Act, with several companies set to receive direct funds in exchange for equity stakes. The announcement sent quantum stocks sharply higher across the board, even for companies not named as direct recipients.The following month, on June 22, 2026, a pair of executive orders turned that broad funding narrative into a structured federal timeline. One directive targets national quantum computing and sensing capabilities, coordinating multiple agencies to deliver a science-enabling quantum computer to a Department of Energy facility later this decade. A second focuses on cryptographic defense, directing federal agencies to begin migrating high-value systems to post-quantum cryptography. For a sector where nearly every pure-play company still burns cash, the alignment of federal policy behind its success has put a floor under valuations that pure speculation never could.The Computing Race: Different Bets on the Same FutureOne fact matters more than any single stock: no one yet knows which quantum architecture will scale best. That uncertainty is the defining feature of the sector, and it is why the public companies pursuing quantum computing look so different from one another.IonQ (NYSE: IONQ) is the largest pure-play by revenue and the name many institutions reach for first. It builds trapped-ion systems prized for high fidelity and long qubit coherence, and it has pushed into quantum networking as a hedge on where near-term revenue may come from. Its business rests on hardware plus partnerships with major cloud platforms and government programs.Rigetti Computing (Nasdaq: RGTI) takes the superconducting path, building modular chips optimized for scalability and selling access to its systems through the cloud. The company has pursued a government-contract-first strategy and signed a letter of intent with the Department of Commerce for a proposed award of up to $100 million over three years under the CHIPS Act build-out.D-Wave Quantum (NYSE: QBTS) occupies a distinct position, having built its business on quantum annealing, a specialized technique well suited to optimization problems rather than universal gate-based computing. It has more recently added a gate-model platform, giving it two fundamentally different approaches under one roof.IBM (NYSE: IBM) and Alphabet (Nasdaq: GOOGL) anchor the big-cap end of the field, where quantum is upside rather than survival. IBM has published one of the most detailed roadmaps in the industry, targeting a demonstration of quantum advantage by the end of 2026 and a large-scale, fault-tolerant system it calls Starling by 2029. Alphabet's Google Quantum AI drew wide attention with error-correction progress on its Willow chip. Both carry the balance sheets to keep pushing regardless of near-term commercial results.The Other Half of the Story: Securing the Quantum EraRunning alongside the computing race is a second, less flashy contest with a firmer deadline: replacing the encryption that protects nearly all sensitive data today before quantum machines grow powerful enough to break it. The concern is not hypothetical. Security researchers describe a "harvest now, decrypt later" dynamic, in which encrypted data is captured today on the expectation it can be unlocked once the technology matures.The regulatory calendar has sharpened that concern. In August 2024, the National Institute of Standards and Technology finalized its first three post-quantum cryptography standards, and the U.S. National Security Agency's CNSA 2.0 framework sets a phased timeline for national security systems to adopt quantum-safe algorithms over the balance of the decade. Those deadlines have turned what was long a strategy-document abstraction into an operational project for enterprises and governments alike.That is the lane QSE - Quantum Secure Encryption Corp. (CSE: QSE) (OTCQB: QSEGF) (FSE: VN8) operates in. The Canadian company describes itself as a post-quantum cybersecurity firm focused on quantum-resilient data protection, identity security, secure storage, and cryptographic migration readiness. In March 2026 it launched QPA v2, an enterprise platform designed to help organizations assess where their encryption is exposed, inventory cryptographic dependencies, and plan a migration to quantum-safe standards. Other names positioned across the post-quantum security stack include established security vendors and specialists such as Arqit Quantum (Nasdaq: ARQQ), alongside larger platform players. As with the computing names, these companies operate at very different scales and pursue different models.The Case for CautionFor all the momentum, the quantum sector remains among the most speculative corners of the market. The industry still operates in what researchers call the NISQ era, noisy intermediate-scale quantum, where today's leading systems top out in the low hundreds to low thousands of physical qubits and require aggressive error correction. There is still no commercial killer application running at scale on quantum hardware, and useful chemistry, cryptography, and optimization workloads at scale remain a late-decade story by most estimates.The financial profile reflects that. Pure-play quantum companies trade at extreme valuations relative to minimal revenue, regularly raise equity to fund research, and expose shareholders to dilution and steep volatility. Architectures can go obsolete if a rival reaches fault-tolerance first. Government funding has put a floor under the sector, but policy is a tailwind, not a guarantee, and execution against technical roadmaps remains the ultimate test. For most risk-aware investors, the takeaway from the analysts covering the space is consistent: treat quantum as a small, diversified, long-horizon position rather than a sure thing.The Bottom LineQuantum in 2026 is a sector finally backed by real money and real milestones, and still years from proving its commercial thesis. The computing names are placing different architectural bets on the same uncertain future, the big-cap programs are funding the frontier, and a parallel security race is running against fixed deadlines that do not depend on any single company succeeding. For investors watching the theme, the sector rewards breadth and patience over conviction in any one name, and the next checkpoints, hardware milestones, funded roadmaps hitting their dates, and enterprise adoption of post-quantum tools, are the markers worth watching from here.SIGNAL OVER NOISESignal over noise. Quantum-computing and cybersecurity headlines move fast, and the crowd often moves first. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow, and trending tickers as they happen, so you see the move forming instead of reading about it later. See it at eagle-eye.dev.CONTACTUSA News Group
info@usanewsgroup.comSOURCES[1] U.S. Department of Commerce quantum funding under the CHIPS and Science Act, announced May 2026; contemporaneous market coverage, 2026.
[2] Executive orders on national quantum capabilities and cryptographic defense, signed June 22, 2026; contemporaneous coverage, 2026.
[3] IBM Quantum roadmap and corporate disclosures, 2025-2026.
[4] QSE - Quantum Secure Encryption Corp. (CSE: QSE), corporate disclosures and news releases, 2026, including the QPA v2 launch dated March 31, 2026.
[5] IonQ, Inc. (NYSE: IONQ); Rigetti Computing, Inc. (Nasdaq: RGTI); D-Wave Quantum Inc. (NYSE: QBTS); Arqit Quantum Inc. (Nasdaq: ARQQ), corporate disclosures and market data, 2026.DISCLAIMERNothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed for Market IQ Media Group Limited, a company incorporated under the laws of Ireland ("MIQL"), which wholly owns and operates USA News Group. MIQL has previously been paid a fee for QSE - Quantum Secure Encryption Corp. advertising and digital media, which fee has since expired. There may be 3rd parties who may have shares of QSE - Quantum Secure Encryption Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constituted a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. MIQL and its owner/operators own shares of QSE - Quantum Secure Encryption Corp. acquired through private placement and in the open market, and reserve the right to buy and sell shares of QSE - Quantum Secure Encryption Corp. at any time without any further notice commencing immediately and ongoing. This article is a general overview of the quantum technology sector and is intended for informational and industry-context purposes only. None of the companies named in this article, including QSE - Quantum Secure Encryption Corp., has reviewed, approved, endorsed, commissioned, or is responsible for the content of this article, and nothing herein should be construed as a statement by, or on behalf of, any company mentioned. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. All references to companies named in this article are based on those companies' public disclosures, are provided for industry context only, and do not imply any partnership, endorsement, affiliation, or comparable performance.FORWARD-LOOKING STATEMENTS: This publication contains forward-looking statements, including statements regarding the growth of the quantum computing and post-quantum security sectors; government funding and policy timelines; the technology roadmaps, milestones, and commercial prospects of the companies referenced; and the pace of enterprise and government adoption of quantum-safe cryptography. Forward-looking statements are based on current expectations and assumptions and are subject to known and unknown risks and uncertainties, many beyond any company's control, including the technical difficulty of scaling quantum hardware and achieving fault tolerance; the risk that a given architecture is superseded; the substantial capital requirements and dilution risk facing early-stage companies; uncertain timing and terms of government funding; competition from larger and better-capitalized companies; and the pace at which regulatory deadlines translate into commercial demand. Actual results could differ materially from those projected. References to other companies are based on those companies' public disclosures, are provided for industry context only, and do not imply any partnership, endorsement, affiliation, or comparable performance. Except as required by law, none of the companies referenced undertakes any obligation to update any forward-looking statement.  View original content to download multimedia:https://www.prnewswire.com/news-releases/the-quantum-sector-hits-an-inflection-point-federal-money-real-milestones-and-a-security-race-running-in-parallel-302818222.html Original: The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel

As AI Models Become Commodities, a Bio-Native AI Company Just Moved to Patent the Data Layer Beneath the ModelsJuly 6, 2026 8:55 AM
PR Newswire (Canada) Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ: HYFT) filed a European patent application directed to the high-dimensional biological data architecture beneath its HYFT® Technology, ReefIQ™, and LensAI™, the model-agnostic context layer designed to let AI models and agentic workflows retrieve, compare, and reason over connected, traceable biology in drug discovery.AUSTIN, Texas, July 6, 2026 /CNW/ -- USA News Group News Commentary — A growing consensus in artificial intelligence holds that the models themselves are becoming interchangeable, and that durable advantage is migrating away from the model and toward the proprietary, structured data a model reasons over. On that thesis, MindWalk Holdings Corp. (NASDAQ: HYFT), a Bio-Native AI company, has filed a European patent application directed to the high-dimensional data structures at the core of its HYFT® Technology, moving to protect the enriched biological data layer that its commercial platforms are designed to run on. Key TakeawaysMindWalk Holdings Corp. (NASDAQ: HYFT) filed European patent application No. EP26187897.9, directed to high-dimensional data structures for biological subsequences and property inference, intended to protect the enriched biological representation architecture beneath its HYFT® Technology, ReefIQ™ biological context layer, and LensAI™ reasoning workflows.The filing rests on a thesis gaining traction across life-sciences AI: as frontier models trend toward commodity, durable advantage migrates to the data layer, the structured, domain-specific representation that lets any model or agent retrieve, compare, and reason over biology with traceable context.The application is described as additive to MindWalk's foundational HYFT patent (WO 2020/161344), protecting a distinct computational layer built on the original foundation rather than a re-filing of it, and anchoring a market where spending on AI in drug discovery is projected to grow from roughly US$5 billion in 2026 to more than US$8 billion by 2030, atop more than US$250 billion in annual pharmaceutical R&D.MindWalk is advancing amid broader activity in AI-enabled life sciences, a landscape that includes public names investors track such as Absci (NASDAQ: ABSI), Certara (NASDAQ: CERT), AstraZeneca (NASDAQ: AZN), and NVIDIA (NASDAQ: NVDA), each distinct, and none a proxy for MindWalk.Patenting the Layer Beneath the ModelThe premise behind the filing is that in artificial intelligence, the models are becoming easier to substitute. As frontier systems from competing labs converge on similar capabilities, MindWalk argues the place where lasting advantage accrues is shifting away from the model and toward the proprietary, structured data the model is given to reason over. On June 2026, the Austin-based Bio-Native AI company announced it filed European patent application No. EP26187897.9, directed to high-dimensional data structures for biological subsequences and property inference. The application is intended to protect the enriched biological representation architecture that underpins its HYFT® Technology, its ReefIQ™ biological context layer, and its LensAI™ reasoning workflows."Every AI model eventually becomes easier to substitute; the durable question is what biological context the model runs on," said Jennifer Bath, Ph.D., Chief Executive Officer and President of MindWalk. "In life sciences, the differentiator is not a generic chatbot layer, but the structured representation that lets models and agentic workflows retrieve connected evidence, preserve provenance, and reuse knowledge across programs. This filing is intended to protect aspects of the architecture at the core of HYFT® Technology, where MindWalk believes lasting value in biological AI can compound."The company frames the timing against a clear architectural lesson emerging in agentic AI for life sciences: frontier models alone are not enough. It points to recent public work on scientific agents, including NVIDIA's BioNeMo Agent Toolkit and AstraZeneca's ChatInvent system, as evidence of the need for domain-specific context, structured tool interfaces, provenance, memory, and validation when AI agents are deployed in real scientific workflows.An Additive Layer, Not a Re-FilingThe new application builds on MindWalk's foundational HYFT patent (WO 2020/161344), which established how the company identifies characteristic biological patterns that recur across life and uses them as a searchable language to compare sequences without alignment. According to MindWalk, EP26187897.9 protects a distinct and additive layer, organizing the biological meaning around those patterns into a form that can be reused across the company's infrastructure, customer programs, and AI workflows. The company describes it as the computational layer built on the original foundation, not a re-filing of it.The contrast the company draws with a model-only approach is central to its argument. Large language models are powerful, MindWalk notes, but their learned knowledge is largely embedded in model parameters and can be difficult to inspect, update, or govern in a biological discovery setting. Its architecture is designed to add a separate, biology-aware representation layer that keeps meaningful biological patterns connected to sequence-level, structural, physicochemical, functional, experimental, and literature-derived context in a form that can be retrieved, compared, updated, and reused across workflows, evolving as new biological knowledge is generated rather than requiring every insight to be absorbed into a new model-training cycle.The work targets a persistent obstacle in drug discovery: fragmented data. A single program may generate sequence information, structural context, physicochemical signals, assay results, literature evidence, and historical decisions across different systems and teams. When that context is scattered, MindWalk argues, scientists and AI systems lose information that should remain connected, and the company's architecture is designed instead to keep each meaningful biological pattern tied to the context that explains why it matters."Biology does not live in one file type," said Dirk Van Hyfte, M.D., Ph.D., Chief Technology Officer of MindWalk. "Sequence, structure, physicochemical behavior, function, evidence, and literature all need to stay connected for AI systems to be useful in discovery. Through this filing, we are seeking to protect the layer that keeps those biological connections organized, accessible, and usable as discovery work moves between AI models, software tools, and human scientific teams."From Architecture to Active ProgramsMindWalk says it has begun to demonstrate the approach in active programs, with results the company is careful to frame as preclinical. In dengue, the company has reported preclinical binding-level data in which a HYFT®-identified target informed immunogen design and generated antibodies that bound across antigens from all four dengue serotypes in two independent campaigns. In influenza, MindWalk has disclosed a HYFT®-defined functional constraint observed across broad influenza A and B datasets, including human, avian, swine-associated, Victoria, and Yamagata backgrounds. These programs remain preclinical, and the company states that additional studies are required to assess neutralization, safety, durability, clinical translation, regulatory path, and commercial potential.The approach reflects what MindWalk calls its functional and evolutionary-constraint thesis: that recurring biological patterns often persist because they are tied to function, structure, binding, immune recognition, or evolutionary fitness. By representing those patterns together with their surrounding context, the company aims to give AI systems a more organized and traceable basis for reasoning over biology.The Commercial Layer and Why It Matters to InvestorsReefIQ™ and LensAI™ are the commercial expression of this representation strategy. The company states that LensAI™ is in contracted, recurring arrangements with life-sciences customers today, and that the filing is intended to protect a layer those deployments can build on as data and program experience accumulate. In MindWalk's framing of the stack, HYFT® identifies biologically meaningful pattern anchors, ReefIQ™ organizes customer and program data around those anchors as governed biological context, and LensAI™ operates over that context to support target discovery, candidate diligence, hypothesis generation, and portfolio decision support.That data layer also anchors a large and growing market. By the company's cited third-party estimates, spending on AI in drug discovery is projected to grow from approximately US$5 billion in 2026 to more than US$8 billion by 2030, atop the more than US$250 billion the pharmaceutical industry invests in research and development each year. Those figures are third-party projections that may prove inaccurate, and the company presents them as context. For investors, MindWalk frames the filing as support for a strategy of building value beyond any single AI model, with the durable asset being the biology-aware representation layer itself, a model-agnostic infrastructure asset the company believes can become more valuable as more programs, evidence, and customer data are connected to it.The Public Companies Around AI-Enabled Drug DiscoveryMindWalk is a Bio-Native AI company pursuing an infrastructure strategy and is not directly comparable to the names below. These comparisons are for industry context only; each company pursues a different technology and business model, several are far larger or further along, and none is a proxy for MindWalk or implies any partnership or comparable performance.Absci (NASDAQ: ABSI) is a clinical-stage biopharmaceutical company that applies generative AI and synthetic biology to design antibody therapeutics, pairing AI models with high-throughput wet-lab validation. Absci illustrates the AI-native, model-plus-wet-lab end of drug discovery, a different approach to the shared goal of making AI useful in real biological workflows.Certara (NASDAQ: CERT) provides biosimulation and model-informed drug-development software used across pharmaceutical R&D. As an established software-and-services provider to drug developers, Certara offers a view of the software-infrastructure layer of the industry that platform-stage companies are working within.AstraZeneca (NASDAQ: AZN), a global biopharmaceutical company, has publicly detailed agentic-AI work in discovery, including the ChatInvent system referenced in connection with MindWalk's filing. AstraZeneca represents the large-pharma end of the spectrum, where major developers are building and deploying agentic AI inside real discovery workflows.NVIDIA (NASDAQ: NVDA) supplies much of the compute and software infrastructure behind modern AI, including life-sciences tools such as its BioNeMo Agent Toolkit referenced in connection with the filing. NVIDIA illustrates the compute-and-tooling foundation on which AI-enabled discovery, including the kind of agentic workflows MindWalk describes, is being built.The Bottom LineA patent application is a beginning, not a guarantee. European examination can narrow or reject claims, and the scope, issuance, enforceability, and competitive value of any patent that ultimately issues remain open questions the company itself flags, alongside the preclinical status of its dengue and influenza programs. But the strategic signal is coherent: in a world where AI models are trending toward commodity, MindWalk is betting that lasting value in life-sciences AI lives in the structured biological data underneath, and it is moving to protect its version of that layer at the architectural root. For investors tracking where durable advantage accrues as the AI buildout matures, MindWalk's filing is a concrete data point, with the patent's prosecution, customer adoption, and revenue trajectory the markers worth watching from here.SIGNAL OVER NOISESignal over noise. Biotech, artificial-intelligence, and drug-discovery headlines move fast, and the crowd often moves first. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow, and trending tickers as they happen, so you see the move forming instead of reading about it later. See it at eagle-eye.dev.CONTACTUSA News Group
info@usanewsgroup.comSOURCES[1] MindWalk Holdings Corp., "MindWalk (NASDAQ: HYFT) Files Patent for High-Dimensional Biological Data Architecture Powering AI Drug Discovery" (Business Wire, AUSTIN, Texas, 2026; European patent application No. EP26187897.9; HYFT®, ReefIQ™, LensAI™; foundational HYFT patent WO 2020/161344).[2] Absci Corporation (NASDAQ: ABSI), corporate and clinical disclosures, 2026.[3] Certara, Inc. (NASDAQ: CERT), corporate disclosures, 2026.[4] AstraZeneca PLC (NASDAQ: AZN), corporate disclosures; ChatInvent agentic system described in He J, Lai H, Saigiridharan L, Ghiandoni GM, et al., "Democratising real-world drug discovery through agentic AI," Drug Discovery Today, 2026.[5] NVIDIA Corporation (NASDAQ: NVDA), corporate disclosures; BioNeMo Agent Toolkit, NVIDIA Developer Blog, 2026.[6] AI-in-drug-discovery market estimates (Fortune Business Insights; Astute Analytica) and pharmaceutical R&D spending (Fierce Biotech; Statista), cited for context.DISCLAIMERNothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed by USA News Group on behalf of Market IQ Media Group Limited, a company incorporated under the laws of Ireland ("MIQL"). MIQL has been paid a fee for MindWalk Holdings Corp. advertising and digital media from Creative Direct Marketing Group ("CDMG"). There may be 3rd parties who may have shares of MindWalk Holdings Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. MIQL and its owner/operators do not own any shares of MindWalk Holdings Corp., but reserve the right to buy and sell shares of MindWalk Holdings Corp. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQL has been reviewed and approved on behalf of MindWalk Holdings Corp. by CDMG. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.FORWARD-LOOKING STATEMENTS: This publication contains forward-looking statements, including statements regarding European patent application No. EP26187897.9 and the prosecution, scope, issuance, enforceability, and competitive value of any patent that may issue; the possibility that claims may be narrowed, rejected, or successfully challenged; the role of the patented architecture in HYFT® Technology, ReefIQ™, the biological representation, and the LensAI™ platform; risks that preclinical results described, including the dengue binding-level data and the influenza functional-constraint findings, may not be reproduced and may not translate into neutralization, safety, efficacy, durability, or clinical or commercial success, and that these programs remain preclinical and subject to substantial further study; the size, growth, and addressability of the markets referenced, which are based on third-party estimates that may prove inaccurate; the pace and degree of customer and market adoption; the technical performance of AI-based discovery methods; competition; regulatory determinations; and capital-markets conditions. Additional information is available in MindWalk's Annual Report on Form 20-F and other filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov/edgar). Except as required by law, MindWalk undertakes no obligation to update any forward-looking statement. References to other companies are based on those companies' public disclosures, are provided for industry context only, and do not imply any partnership, endorsement, affiliation, or comparable performance. HYFT® is a registered trademark, and LensAI™ and ReefIQ™ are trademarks, of MindWalk Holdings Corp. or its subsidiaries.Logo - https://mma.prnewswire.com/media/2838876/5656770/USA_News_Group_Logo.jpg  View original content:https://www.prnewswire.com/news-releases/as-ai-models-become-commodities-a-bio-native-ai-company-just-moved-to-patent-the-data-layer-beneath-the-models-302818260.html Original: As AI Models Become Commodities, a Bio-Native AI Company Just Moved to Patent the Data Layer Beneath the Models

ABSI here we go blue sky break 11.00…the AI bio beast of 2026

Sold at 9.31 - this was never high on my hot list, 286% from $2.56 SO BYE BYE

Absci Shares Soar After Positive Early Clinical Results for Hair Loss Therapy (ABSI)June 24, 2026 8:59 AM
IH Market News Absci Corporation (NASDAQ:ABSI) shares surged 24% on Wednesday after the biotechnology company reported encouraging interim Phase 1 safety data for ABS-201, its experimental antibody treatment for hair loss. The results provided an early boost to investor confidence as the company advances the candidate through clinical development for androgenetic alopecia, the most common form of hair loss. Phase 1 Trial Meets Key Safety Objectives According to Absci, ABS-201 was generally well tolerated across all blinded single ascending dose cohorts evaluated in the ongoing study. The trial enrolled 32 healthy adult participants who received intravenous doses ranging from 150 mg to 1,800 mg across four separate cohorts. The company reported no serious adverse events during the study. Most treatment-emergent adverse events were classified as mild, with the only moderate event being a headache reported in the third cohort. Investigators determined that the event was unlikely to be related to the treatment. The favorable safety profile supports continued development of the therapy and progression into subsequent stages of testing. ABS-201 Targets Androgenetic Alopecia ABS-201 is an anti-prolactin receptor antibody being developed to treat androgenetic alopecia, a condition that affects an estimated 80 million people in the United States. The therapy is designed to target biological pathways associated with hair loss and could offer a differentiated treatment approach compared with currently available options. Pharmacokinetic data from the study indicated an estimated half-life of at least 65 days. According to the company, the long duration of activity could support a treatment schedule involving only two or three injections over a six-month period. Multiple-Dose Study Already Underway Following the positive initial safety findings, Absci has begun enrolling participants in the first multiple ascending dose cohort involving individuals diagnosed with androgenetic alopecia. The next stage of the study is expected to provide important insights into the drug’s efficacy and its ability to promote meaningful clinical improvements in hair growth. Management expects to release interim proof-of-concept results during the second half of 2026. Full proof-of-concept data are anticipated in early 2027. Company Raises $100 Million to Support Development Pipeline Alongside the clinical update, Absci announced the pricing of an underwritten public offering consisting of 13.5 million shares. The shares were priced at $7.41 each and are expected to generate gross proceeds of approximately $100 million before underwriting fees and related expenses. The financing attracted participation from several prominent healthcare and institutional investors, including Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile and another large investment management firm. Funding to Advance Hair Loss and Endometriosis Programs Absci said the proceeds will be used to support the continued development of ABS-201 in both androgenetic alopecia and endometriosis. The company also plans to launch a Phase 2 clinical trial for endometriosis later this year. The successful financing strengthens Absci’s balance sheet and provides additional resources to advance multiple programs through key clinical milestones. Investors Focus on Upcoming Efficacy Data The strong market reaction reflects growing investor optimism following the positive safety results and the company’s ability to secure significant new capital. With proof-of-concept data expected over the next 12 months and additional clinical studies planned, investors are increasingly focused on whether ABS-201 can demonstrate meaningful efficacy in treating hair loss and support its potential as a future commercial product. The latest results mark an important step forward for the program as Absci continues building its clinical pipeline in areas of significant unmet medical need. Absci Corporation stock priceThe post Absci Shares Soar After Positive Early Clinical Results for Hair Loss Therapy (ABSI) appeared first on US Editors. Original: Absci Shares Soar After Positive Early Clinical Results for Hair Loss Therapy (ABSI)

Nice bounce on the offering.

Where are you clown

The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath ItJune 16, 2026 8:45 AM
PR Newswire (US) Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /PRNewswire/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually building these systems: in biology, the model may be the least durable part of the equation. Models improve, get copied, and get commoditized. What is hard — and potentially far more valuable — is the connected, trustworthy biological knowledge the model has to reason over in the first place. Feed even a brilliant model fragmented, contradictory data and it will, in the words of one industry executive, confidently get it wrong. That debate moves to center stage on June 15, 2026, when MindWalk Holdings Corp. (NASDAQ: HYFT) joins a virtual investor panel hosted by research firm Jones — alongside generative-biology company Absci (NASDAQ: ABSI) and a leading AI compute provider — titled "Partnering to Power the New Era of Drug Discovery." The panel is a small event, but it sits on top of one of the most consequential questions in biotech: as the industry pours capital into AI, what is the part that actually compounds in value? MindWalk's answer — and the trajectory of the broader field — is worth understanding now, because it reframes where the durable advantages in AI-driven medicine may ultimately lie.Why AI Drug Discovery Hit a Wall — and What ChangedThe promise of applying AI to drug discovery has always been intoxicating: compress the decade-plus, billion-dollar odyssey of finding and validating a new medicine into something faster, cheaper, and more likely to succeed. The early wave of "AI-first" biotechs raised enormous sums on that promise. But the field ran into a hard truth that has little to do with algorithms. Biological data is a mess. It is scattered across incompatible files, formats, instruments, lab notebooks, and decades of literature; it is riddled with gaps and contradictions; and the relationships that matter most — how a sequence maps to a structure, a function, a mechanism, a disease — are often implicit rather than recorded. A model trained or prompted on that fragmented foundation can produce fluent, confident answers that are simply wrong, a failure mode the field has come to call hallucination.In consumer applications, a hallucinating chatbot is an annoyance. In drug discovery, it is a multimillion-dollar wrong turn, sending scientists down a path toward a target or molecule that was never viable. As the industry now races to deploy not just static AI models but autonomous "agentic" systems — AI that can plan and execute multi-step research workflows with limited human supervision — the cost of bad underlying data multiplies. An agent acting on fragmented biology does not just give one wrong answer; it compounds the error across an entire chain of decisions. That escalating risk is exactly why attention is shifting from the models themselves to the integrity of the biological foundation they operate on.MindWalk's Bet: Own the Context Layer, Not the ModelMindWalk — a company that rebranded in 2025 from its prior identity as ImmunoPrecise Antibodies, unifying its operations and adopting the Nasdaq ticker HYFT — has built its entire strategy around that shift. Rather than competing to build the flashiest model, the company positions its durable asset as the layer underneath: a biological "context layer" that connects and enriches data before any model reasons over it. Its proprietary HYFT® Technology, refined over roughly two decades of curation, is described as a continuously evolving biological representation spanning 660 million biological patterns and 25 billion relationships — a kind of connective tissue that links sequences, structures, functions, mechanisms, pathways, evidence, and literature into a single queryable foundation.On top of that foundation sit two products the company has brought to market. ReefIQ™, launched in June 2026, is pitched as the biological context layer that sits between a client's fragmented discovery data and its AI reasoning workflows — reconnecting the pieces before the AI acts. LensAI™ is the reasoning and application layer used for target discovery, candidate diligence, and portfolio decision support, and increasingly to host the agentic workflows pharma is racing to adopt. The company's central thesis, which CEO Dr. Jennifer Bath is expected to articulate on the Jones panel, is that because its predictions are grounded in what evolution has already conserved — the functional patterns that have survived across biology — rather than in raw statistical correlation, the system is designed to keep both models and agents from hallucinating in the highest-consequence workflows. Bath has framed the convergence she sees as "biology, context, and compute."Importantly, this is not purely conceptual. MindWalk reported that its largest enterprise AI client signed a one-year LensAI platform contract — the first contracted, recurring platform-revenue agreement in the company's history — and that the structure is one it intends to scale across its client base. For its fiscal third quarter ended January 31, 2026, the company reported revenue of $4.2 million (in Canadian dollars), up 52% year-over-year and a third consecutive quarter of year-over-year growth, with U.S. revenue doubling. The company also reported preclinical dengue data that, by its account, supported a computational prediction its platform generated before any animal was immunized — an early, real-world validation of the approach.The Field Around MindWalkMindWalk is one expression of a sector that has matured well beyond the first hype cycle, and looking at how a few public peers are positioned helps frame both the opportunity and where MindWalk's niche sits within it. Each of these companies attacks the AI-drug-discovery problem from a different layer of the stack.Absci Corporation (NASDAQ: ABSI) — MindWalk's fellow panelist — represents the generative-design frontier. The company uses generative AI models paired with an integrated wet lab to design therapeutic antibodies essentially from scratch, conditioning its models on a target's structure and then validating proposals through high-throughput experiments. Absci became clinical-stage with an AI-designed antibody entering a Phase 1 trial, making it a closely watched proof point for whether generative design can produce real drugs. It illustrates the "design" layer of the field — complementary to the data-foundation layer MindWalk emphasizes.Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is among the largest and best-known "AI-first" drug discovery platforms, having industrialized the generation of biological data through massive automated experimentation and paired it with machine learning to identify drug candidates. With collaborations involving major pharmaceutical companies and its own clinical-stage pipeline, Recursion represents the scaled, full-stack ambition of the sector — building both the data engine and the drug pipeline — and the patient capital that strategy requires.Schrödinger, Inc. (NASDAQ: SDGR) approaches the problem from a different intellectual tradition: physics-based computational chemistry. Its software platform simulates how molecules behave at a fundamental level to predict which candidates are worth pursuing, and it both licenses that software to the industry and advances its own pipeline. Schrödinger illustrates the established, software-led end of the field — a reminder that "computational drug discovery" predates the current AI wave and that different modeling philosophies coexist and compete.Certara, Inc. (NASDAQ: CERT) rounds out the group as the infrastructure-and-decision-support comparison closest in spirit to MindWalk's positioning. A leader in biosimulation and model-informed drug development, Certara provides software and AI-powered services used across the drug-development lifecycle, including in regulatory submissions. As one of the more established, revenue-generating names in the space, it demonstrates that there is a durable, infrastructure-layer business in AI-enabled drug development — the same category MindWalk is targeting with its context layer, albeit at a far larger and more mature scale. These companies are referenced to illustrate the sector and do not imply any partnership, endorsement, affiliation, or comparable financial performance; they differ widely in approach, size, and stage, and MindWalk is among the smaller, earlier-stage names. References to Absci, Jones, and the other panelists describe the event only and do not imply any endorsement or commercial relationship.The Investment Case — and the RisksThe bull case for the context-layer thesis is conceptually elegant. If models are destined to commoditize — and the pace at which capable AI models now proliferate suggests they might — then the enduring value in AI drug discovery accrues to whoever owns the trusted, connected biological foundation that every model and agent must rely on. A context layer, in that telling, becomes infrastructure: something pharma rents rather than rebuilds, with recurring revenue and compounding value as more data and more programs run through it. MindWalk's first recurring platform contract and its growing revenue are early evidence that customers may be willing to pay for exactly that.The risks, however, are substantial and should not be minimized. MindWalk is a small-cap company still posting operating losses as it transitions from a legacy wet-lab services business toward a scalable platform model. Its revenue, while growing, is modest in absolute terms, and the company depends on converting engagement into contracted, recurring arrangements that have only just begun. It relies on third-party compute and cloud providers, faces intense competition from larger and better-funded players, and operates in a field where adoption of bio-native and agentic AI could prove slower than hoped. As with any clinical- or platform-stage life-sciences company, there is no certainty that the capabilities described will translate into commercial success, and forward-looking claims about the technology remain just that — forward-looking.A Sector Finding Its Real FoundationWhat makes this moment interesting is not any single company or any single panel. It is that the AI-drug-discovery field appears to be maturing past its first, model-obsessed phase into a more sophisticated understanding of where value actually lives. The lesson emerging from the first wave — that pointing powerful AI at messy biology produces confident nonsense — has pushed serious players toward the unglamorous but essential work of connecting and grounding biological knowledge. Whether the durable advantage ultimately sits in generative design, industrialized data generation, physics-based simulation, or a connected context layer is precisely the question a panel like the one on June 15 exists to debate.MindWalk has placed a clear, focused bet on the context layer — that in the age of agentic AI, the biology has to be connected and trustworthy before a model ever acts on it, and that owning that foundation is the durable prize. It is an early-stage bet, with real execution and financing risk, and the market has yet to render its verdict. But the trajectory of the field is unmistakable: the conversation has moved from "whose model is biggest" toward "whose biology is most trustworthy," and the companies building that foundation are positioning themselves at what may prove to be the most defensible layer of the entire AI-medicine stack. For investors trying to understand where the next decade of drug discovery is headed, that shift is the story worth watching.SEE WHAT THE MARKET IS TALKING ABOUT BEFORE IT MOVESEagle Eye reads social, forum, and news chatter across thousands of investor conversations in real time — and surfaces the tickers the crowd is piling into, along with the sentiment and catalysts behind them.Explore Eagle Eye free (for now) at https://Eagle-Eye.devCONTACT:Equity Insiderinfo @therooster-2873SOURCES:[1] MindWalk Holdings Corp. — "MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel…" (Business Wire, June 12, 2026; primary source for the panel, HYFT/ReefIQ/LensAI platform, Bath quote, 660M patterns / 25B relationships):
https://finance.yahoo.com/sectors/healthcare/articles/mindwalk-nasdaq-hyft-ceo-dr-130000157.html[2] MindWalk Holdings Corp. — "Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery" (Business Wire, June 10, 2026; ReefIQ context-layer detail):
https://www.businesswire.com/news/home/20260610294167/en/MindWalk-Holdings-Corp.-NASDAQ-HYFT-Launches-ReefIQ-a-Biological-Context-Layer-for-AI-Drug-Discovery[3] MindWalk Holdings Corp. — "Reports Q3 Fiscal 2026 Financial Results" (Business Wire, March 12, 2026; $4.2M revenue +52% YoY, first recurring LensAI contract, subsidiaries):
https://www.businesswire.com/news/home/20260312858299/en/MindWalk-Holdings-Corp.-Reports-Q3-Fiscal-2026-Financial-Results[4] MindWalk Holdings Corp. — "ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to 'HYFT'" (Business Wire, Sept 3, 2025; rebrand, platform business-model shift):
https://www.businesswire.com/news/home/20250903938726/en/ImmunoPrecise-Rebrands-as-MindWalk-Announces-NASDAQ-Ticker-Change-to-HYFT[5] BioPharmaTrend — "Publicly Traded AI-driven Drug Discovery Companies" and related sector coverage (peer context: Absci, Recursion, Schrödinger, Certara):
https://www.biopharmatrend.com/artificial-intelligence/recent-ipos-among-ai-driven-platforms-for-drug-discovery-and-biotech-601/DISCLAIMER:Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a digital media distribution and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed by Equity Insider on behalf of MIQ. MIQ has been paid a fee for MindWalk Holdings Corp. advertising and digital media from Creative Direct Marketing Group ("CDMG"). This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article or email as the basis for any investment decision. MIQ does not own shares of MindWalk Holdings Corp. but reserves the right to buy and sell shares of MindWalk Holdings Corp. at any time without any further notice. There may be 3rd parties who may have shares of MindWalk Holdings Corp., and may liquidate their shares which could have a negative effect on the price of the stock. We also expect further compensation as an ongoing digital media effort to increase visibility for the company; no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been reviewed and approved on behalf of MindWalk Holdings Corp. by CDMG; this is a digital media distribution.While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our publication is not trustworthy unless verified by their own independent research. Comparisons to other companies referenced in this publication are for contextual and illustrative purposes only and do not imply any partnership, endorsement, affiliation, or comparable financial performance. References to the Jones AI Day panel, Absci, and other panelists describe the event only and do not imply any endorsement, sponsorship, partnership, or commercial relationship. Forward-looking statements regarding technology, platform adoption, recurring revenue, clinical and preclinical outcomes, and market trends are subject to risks and uncertainties, and actual results may differ materially. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. View original content to download multimedia:https://www.prnewswire.com/news-releases/the-quiet-bottleneck-in-ai-drug-discovery-isnt-the-model--its-the-biology-underneath-it-302800965.html Original: The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

Hello All:
Please take the time to review Helloman1's last 50 or 100 posts.
1. every post is mean spirited and full of hate
2. no posts are positive or encouraging.
we may conclude that this person is bitter and very unhappy in life.
throwing negativity and spewing harsh words is a sign of bigger things going on in (his) life.
3. Let's keep this in mind, ignore all of his posts, and feel sorry for this (pre dementia/ bi-polar/ shitzophrenic) loser.

Thank you for your attention to this matter.👍️

Stay away from this garbage.

ABSI THE BIO BEAST A BEASTVILLE...WEEKLY SMASH AND GRAB BREAK OUT

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 4, 2026

Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on May 1, 2026, the company granted a non-statutory stock option to purchase an aggregate of 276,200 shares of its common stock to one newly-hired non-executive employee. The inducement grant was previously approved by the Compensation Committee of Absci’s Board of Directors pursuant to Absci’s 2023 Inducement Plan (the “Inducement Plan”), and is being made as an inducement material to the new employee’s acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option award has an exercise price of $4.92 per share, the closing price of Absci’s common stock on the Nasdaq Global Select Market on May 1, 2026 the (“Grant Date”). The stock option has a 10-year term and vests over four years, and 25% of the shares subject to the option vest and become exercisable on the one-year anniversary of the Grant Date and the remaining 75% of the shares subject to the option vest and become exercisable in 36 approximately equal monthly installments thereafter such that the shares underlying the option granted to the new employee will be fully vested on the fourth anniversary of the Grant Date, subject to the new employee’s continued service with Absci on each such date (subject to the terms and conditions of the Inducement Plan and the option award agreement covering the grant).

About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.

Absci® standard character mark, ABS-201™, and Integrated Drug Creation™ are trademarks and registered trademarks of Absci Corporation.

Investor Contact
Alexander D.H. Khan
Corporate Vice President
Head of Investor Relations
investors@absci.com

Media Contact
press@absci.com

Link article

$ABSI 🗞️

ABSI the bio beast that nobody is talking about

BIO BEAST BEASTING THROUGH BEASTVILLE

ABSI time for this bio to shine once again

I saw good news in report. 201 advancing. Good spot to.be in

40 million share short 18 days to cover last month it was 11 there's only about 40 million available shares to trade 80% close to of the 150 million are held by institutions which I'm sure some are leveraged short. Technically we're a 100% shorted. I'm holding 32,000 shares and I'm not selling until I hit six

Short interest. Ridiculous 25% of shares.
Have some good news please!

Someone tell GameStop boys. Lol

ABSI. Beautiful close to exit.

ABSI. Beautiful close. One more push!

ABSI. Bios hot breaking on weekly

ABSI. Bios hot breaking on weekly

ABSI. Bios hot breaking on weekly

$ABSI: With Oracle related news this Morning.... now $2.50

Remember....... today is 9/11


LIFE IS FLEETING.

Now........ hug your loved ones.... be kind............ AND MAKE SOME MEGA MONEY !!!!!!!!!


GO $ABSI

Short squeeze??? Looks good for one

Share Structure & Short Metrics
Outstanding shares: ~127.6?M

Float (public shares available): ~111.5?M StockAnalysis+11MarketBeat+11Seeking Alpha+11

Short interest: ~32.1?M shares, which is 28.8% of float (or ~25% of total shares) MarketBeat+1MarketBeat+1

Days to cover: ~9–10?days (varies by source: ~9.9 from MarketBeat, ~8.7 from StockAnalysis, ~6.7 from Fintel/Benzinga) Fintel+3MarketBeat+3Benzinga+3

Short interest trend: A ~23% increase in short interest in June, from ~26?M to ~32?M shares StockAnalysis+2MarketBeat+2Reddit+2

🔍 What This Means for a Possible Short Squeeze
A short squeeze is more likely when:

High short interest as percentage of float (=20%)

Elevated days to cover ratio (=5 days)

Catalysts like positive news or spikes in buying volume

ABSI checks the first two boxes:

Nearly 29% short float—substantially high

8–10 days to cover, indicating shorts would take a long time to unwind

Add in several bullish signals:

AI/ML-driven drug discovery partnerships (e.g., with AMD, Merck, AstraZeneca) Fintel+2Wikipedia+2Reddit+2MarketBeatBenzinga+3MarketBeat+3Fintel+3Wikipedia+5Reddit+5MarketBeat+5Yahoo Finance+10Reddit+10MarketBeat+10

Recent analyst upgrades (Needham, HC Wainwright, Guggenheim) with $7–$10 price targets MarketBeat

If ABSI experiences a strong positive catalyst or sharp price uptrend, the short sellers could be forced to scramble, buying to cover—a textbook setup for a short squeeze.

⚠️ Considerations & Risks
Volatile stock (high beta ~2.0–2.5)—price moves can be exaggerated Reddit+13Fintel+13Newser+13

A squeeze isn't guaranteed—market momentum and broader investor sentiment heavily influence outcomes

Catalyst-dependent—without a strong spark (earnings beat, major partnership, or takeover buzz), the squeeze may not materialize

✅ Bottom Line
ABSI has the classic technical setup for a short squeeze: very high short float, lengthy days to cover, and ongoing bullish interest. If positive news or a surge in buying pressure emerges, a squeeze could follow. But absent that catalyst, the stock may just meander or pull back, even though it's primed structurally.

Black Rock has been ringing the bell. Increase from five percent to over 6%, this quarter . I wonder what they know.

Patience is key with this one

It hasn't woken up yet, but the alarm is ringing. It only takes time..

ABSI MONSTER

GAPPED UP AH...BEAST!

Can it go to $60 next week like TEM or HIMS?

ABSI READY FOR 6.00

ABSI TRENDTRADE WEEKLY BREAK OUT

ABSI NEXT AI CANCER PLAY...MONSTER IN THE MAKING

ABSI: Clueless about it, since back then!! (THANKS for heads-up!!)

ABSI nice day $4s

Wow, President Trump just opened the flood gates for investments into AI and medical approaches. 7.55 before end of February.

Wow, President Trump just opened the flood gates for investments into AI and medical approaches. 7.55 before end of February.

https://www.technologynetworks.com/drug-discovery/articles/how-is-ai-being-used-in-drug-discovery-394789

Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
07:30:00 AM ET, 01/10/2025 - GlobeNewswire

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients.

“At Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. “By combining Absci’s AI de novo design expertise with Owkin’s world-class predictive AI target discovery technology, we have a unique opportunity to design first-in-class and potentially transformative therapeutics for patients in need.”

Through this strategic partnership, Absci and Owkin will co-develop therapeutic candidates addressing novel targets in immuno-oncology and other indications, such as immunology and inflammation. Owkin’s predictive AI models will optimize target selection and validate therapeutic hypotheses using extensive biomedical datasets and patient-derived organoids. Absci’s generative AI Drug Creation platform, including its de novo antibody design models, will rapidly design therapeutic candidates against these novel targets. Together, the companies will aim to streamline and accelerate the path from research to clinical development.

“At Owkin, our mission is to use patient data and Owkin K, our Operating System, to revolutionize drug discovery and development,” said Thomas Clozel, MD, CEO and Co-Founder of Owkin. “This partnership with Absci represents a significant step forward in our journey to bring transformative therapies to patients. By bringing together Owkin’s AI agents that can identify and experimentally validate novel therapeutic targets with Absci’s pioneering capabilities in developing biologic drug candidates, we aim to accelerate the delivery of next-generation treatments.”

This collaboration builds on Absci’s growing portfolio of partnerships with industry leaders such as AstraZeneca and Merck, as well as its robust internal pipeline of drug candidates. With this new partnership, Absci has added drug creation partnerships with four new Partners in 2024, achieving the Company's outlook for the year. Similarly, Owkin has established itself as a pioneer in predictive AI, working with top-tier pharmaceutical companies such as Sanofi and BMS to advance drug discovery and development as well as its differentiated pipeline of drug candidates and AI diagnostics

ProMIS Neurosciences (PMN) announced the initiation of its Phase 1b clinical trial evaluating its lead therapeutic candidate, PMN310, in Alzheimer's disease.Absci Corporation (ABSI) announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients.Tourmaline Bio (TRML) announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, has joined Tourmaline's Cardiovascular Scientific Advisory Board.

AMD is investing $20 million in AI drug startup Absci , which will use AMD chips and software

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Absci (NASDAQ:ABSI) with a Buy and maintains $7 price target.

ABSI: I'm in --- nice deal with AMD!!

3rd quarter results Nov. 12, fyi ANT

2025 gettin' closer, ANT

Approachin' the end of the 6 month tradin' channel, gets interestin' now, fyi imvho ANT

C
A prescription drug bottle filled with 0s and 1s to represent binary code.Francis Scialabba
CFOs are embracing AI, experimenting with new use cases for it throughout the finance function. But some CFOs are tapping the potential of the technology in other ways. At biotech firm Absci, researchers are using AI to develop drugs to treat cancer. (We’re not saying that to make your Claude-drafted emails look bad, we promise.)

Absci’s CFO and CBO, Zach Jonasson, spoke with CFO Brew about how AI is allowing the company to create and test new antibodies faster—and cheaper—than ever before.

Absci uses E. coli—yes, the same bacteria that can give you some nasty infections—to manufacture antibodies that can be used in a variety of therapies. Using a process called “high throughput screening,” it then tests the antibodies, and it patents therapies containing the most promising ones.

Even before ChatGPT burst onto the scene, Absci saw potential in AI. Through its testing of antibodies, the company generated large amounts of data, which it realized could be used to train an AI. In 2021, it acquired a deep learning company called Denovium, which became “the nucleus” that it built a proprietary AI around, Jonasson said.